XXXX sensitivity 19 expression is associated with @entity3 and chemoradiotherapy response in esophageal cancer.

@entity1 @entity10842 @entity900 @entity1721 @entity1206 @entity3
AIM: To investigate the clinical significance of @entity10842 sensitivity 19 (MMS19) expression in @entity1721 ( @entity1721 ). METHODS: Between June 2008 and May 2013, specimens from 103 @entity1 who underwent endoscopic biopsy for the diagnosis of @entity1721 at the endoscopy center of Sun Yat-Sen University Cancer Center were collected; 52 matched-normal esophageal squamous epithelium samples were biopsied as controls. MMS19 protein expression was measured by immunohistochemistry. Of the 103 cases of @entity1721 , 49 received radical surgery following neoadjuvant chemoradiotherapy consisting of concurrent radiation in a total dose of 40 Gy and two cycles of chemotherapy with @entity1206 and @entity900 . Relationships between MMS19 expression, clinicopathologic characteristics and chemoradiotherapy response were analyzed. RESULTS: The MMS19 protein could be detected in both the cytoplasm and nucleus of most specimens. High cytoplasmic expression of MMS19 was detected in 63.1% of @entity1721 samples, whereas high nuclear expression of MMS19 was found in 35.0%. High cytoplasmic MMS19 expression was associated with regional lymph node @entity3 (OR = 11.3, 95%CI: 2.3-54.7; P < 0.001) and distant @entity3 (OR = 13.1, 95%CI: 1.7-103.0; P = 0.002). Furthermore, high cytoplasmic MMS19 expression was associated with a response of @entity1721 to chemoradiotherapy (OR = 11.5, 95%CI: 3.0-44.5; P < 0.001), with a high cytoplasmic MMS19 expression rates in 79.3% and 25.0% of @entity1 from the good chemoradiotherapy response group and poor response group, respectively. Nuclear MMS19 expression did not show any significant association with clinicopathologic characteristics or chemoradiotherapy response in @entity1721 . CONCLUSION: The results of our preliminary study suggest that MMS19 may be a potential new predictor of @entity3 and chemoradiotherapy response in @entity1721 .
